Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 11:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Niaspan Clear all
Terminated Phase 3 Interventional Results available

Niacin Plus Statin to Prevent Vascular Events

NCT00120289
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Cerebrovascular Accident, Coronary Disease, Atherosclerosis, Myocardial Infarction
Interventions
Extended release niacin, Simvastatin
Drug
Lead sponsor
Axio Research. LLC
Industry
Eligibility
45 Years and older
Enrollment
3,414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
68
States / cities
Birmingham, Alabama • Hoover, Alabama • Pheonix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2016 · Synced Sep 23, 2026, 11:35 PM EDT
Not listed Phase 2 Interventional

Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia

NCT02532218
View directory record Official record
Conditions
Hyperlipidemia
Interventions
ARI-3037MO
Drug
Lead sponsor
Arisaph Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
19
States / cities
Chino, California • Fort Lauderdale, Florida • Jacksonvile, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2016 · Synced Sep 23, 2026, 11:35 PM EDT
Withdrawn Phase 1 Interventional

The Effects of MDMA on Prefrontal and Amygdala Activation in PTSD.

NCT03752918
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
MDMA, Niacin
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 23, 2026, 11:35 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+

NCT06919328
View directory record Official record
Conditions
Healthy Aging
Interventions
Niagen®, NAD+, Placebo
Dietary Supplement · Other
Lead sponsor
Nutraceuticals Research Institute
Other
Eligibility
40 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Huntsville, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Sep 23, 2026, 11:35 PM EDT
Completed Phase 3 Interventional Results available

High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly

NCT00127218
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Disease
Interventions
any statin, niacin, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
65 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 23, 2026, 11:35 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

A Study of Niacin Regulation

NCT06175403
View directory record Official record
Conditions
Excessive Weight Gain
Interventions
Niacin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 23, 2026, 11:35 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Benefits of Nicotinamide Riboside Upon Cognition and Sleep

NCT05500170
View directory record Official record
Conditions
Cognitive Impairment, Sleep Quality
Interventions
Nicotinamide riboside, Placebo
Dietary Supplement
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
65 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
3
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 23, 2026, 11:35 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy

NCT05590468
View directory record Official record
Conditions
Mitochondrial Myopathy
Interventions
Nicotinamide Riboside, Placebo
Dietary Supplement · Drug
Lead sponsor
Ralitza Gavrilova
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 23, 2026, 11:35 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome

NCT03789175
View directory record Official record
Conditions
Cancer, Skin Fibroblasts, Muscle Weakness
Interventions
Nicotinamide Riboside (NR)
Dietary Supplement
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Sep 23, 2026, 11:35 PM EDT
Recruiting Phase 3 Interventional

The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer

NCT06861088
View directory record Official record
Conditions
Venous Thromboembolism, Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma
Interventions
Kinisoquin™, Placebo
Drug
Lead sponsor
Quercis Pharma AG
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Ventura, California • Miami Lakes, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 23, 2026, 11:35 PM EDT
Completed Phase 1 Interventional

Psilocybin-assisted Therapy for Phantom Limb Pain

NCT05224336
View directory record Official record
Conditions
Phantom Limb Pain
Interventions
Psilocybin, Placebo Niacin
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 23, 2026, 11:35 PM EDT
Completed Phase 2 Interventional Results available

Study to Test GSK256073 in Patients With Dyslipidemia

NCT00903617
View directory record Official record
Conditions
Dyslipidaemias, Dyslipidemias
Interventions
GSK256073, Placebo, Niaspan
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Pembroke Pines, Florida • Indianapolis, Indiana • Louisville, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Sep 23, 2026, 11:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04991532

NCT01369602
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Healthy
Interventions
PF-04991532
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Anaheim, California • DeLand, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 23, 2026, 11:35 PM EDT
Completed Phase 2 Interventional Results available

Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study

NCT00728910
View directory record Official record
Conditions
Dyslipidemia
Interventions
Atorvastatin, ABT335, ER Niacin
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Sep 23, 2026, 11:35 PM EDT
Not yet recruiting Early Phase 1 Interventional

Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS)

NCT06760533
View directory record Official record
Conditions
IBS - Irritable Bowel Syndrome
Interventions
Psilocybin 25 mg, Psychotherapy Treatment Session, Niacin 100 mg
Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 23, 2026, 11:35 PM EDT
Terminated Phase 3 Interventional Results available

Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy

NCT00108485
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Kidney Failure, Chronic, Hyperlipidemia
Interventions
Extended release niacin, Placebo
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Sep 23, 2026, 11:35 PM EDT
Completed Phase 3 Interventional Results available

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin

NCT01492361
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
AMR101, Placebo, Statin therapy
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
45 Years and older
Enrollment
8,179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
176
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 154 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Sep 23, 2026, 11:35 PM EDT
Active, not recruiting Phase 2 Interventional

Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD

NCT04040959
View directory record Official record
Conditions
Vascular Diseases, Kidney Disease, Blood Pressure, Oxidative Stress
Interventions
Nicotinamide riboside
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
35 Years to 80 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 23, 2026, 11:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Study To Study The Absorption, Metabolism And Excretion Of PF-04991532

NCT01469481
View directory record Official record
Conditions
Healthy
Interventions
PF-04991532
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 30, 2012 · Synced Sep 23, 2026, 11:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse

NCT00699010
View directory record Official record
Conditions
Opioid Abuse
Interventions
Acurox 5/30mg taken first, Oxycodone 5mg taken first
Drug
Lead sponsor
Acura Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Sep 23, 2026, 11:35 PM EDT
Completed Phase 2 Interventional Results available

An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

NCT02890992
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
alirocumab SAR236553 (REGN727), statins, ezetimibe, cholestyramine, fenofibrate, omega-3 fatty acids, nicotinic acid
Drug
Lead sponsor
Sanofi
Industry
Eligibility
8 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
St Louis, Missouri • Charlotte, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Sep 23, 2026, 11:35 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Absorption of Transdermal Vitamins in Post Bariatric Surgery Patients

NCT03360435
View directory record Official record
Conditions
Bariatric Surgery Candidate, Vitamin Deficiency, Mineral Deficiency
Interventions
Patch MD MultiVitamin Plus patch
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Sep 23, 2026, 11:35 PM EDT
Completed Phase 4 Interventional

Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy

NCT01239004
View directory record Official record
Conditions
Dyslipidemia, Hyperlipidemia, Hyperglycemia
Interventions
Placebo, Colesevelam
Drug
Lead sponsor
Radiant Research
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Chicago, Illinois • Kansas City, Kansas • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2012 · Synced Sep 23, 2026, 11:35 PM EDT
Terminated No phase listed Observational

PSIL201 Long-term Follow-up Study: Psilocybin or Niacin / Major Depressive Disorder

NCT04353921
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
No intervention will be administered as part of this study.
Other
Lead sponsor
Usona Institute
Other
Eligibility
21 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Lauderhill, Florida
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 23, 2026, 11:35 PM EDT